A Drug for Treatment of Cancer
A new drug for ovarian cancer by AstraZeneca is being introduced to the Russian market. Olaparib, a polyadenosine-diphosphate-ribose-polymerase (PARP) inhibitor, is a monotherapy agent for maintenance therapy of adult patients sensitive to platinum agents with relapsed serous epithelial ovarian and fallopian tubes cancer. It is also used for treatment of patients with highly malignant primary peritoneal cancer with BRCA1/2 mutation (germinal and/or somatic), who achieved full or partial response to chemotherapy with platinum drugs.
According to Vladimir Bulatov, Medical Director of AstraZeneca Russia and Eurasia, this drug is a new milestone in treatment of cancer patients, which also significantly improves their quality of life.
Trade name: Lynparza a cancer drug
Astra Zeneca announced introduction into the Russian market a new drug for treatment of ovarian cancer. The drug is an inhibitor of poly-adenosine diphosphate ribose polymerase (PARP) using DNA reparation abnormalities to cause death of tumor cells. It is the first PARP inhibitor approved in patients with ovarian cancer with BRCA mutation, sensitive to platinum drugs. The new agent will be available to patients in September.
According to instruction olaparib is recommended as a monotherapeutic agent for maintenance treatment of adult patients with relapsed serous epithelial ovarian and fallopian tube cancer sensitive to platinum agents and highly malignant primary peritoneal cancer with BRCA1/2 gene mutation (germinal or somatic), who achieved full or partial response to platinum agents.
Ovarian cancer with BRCA mutation is the 7th cause of cancer in diagnosed women globally. Mortality due to ovarian cancer ranks 8th among causes of death in women with cancer: in 2012 about 150 thos women died because of ovarian cancer2. The rate of BRCA gene mutation in patients with ovarian cancer exceeds 15%. This mutation is the most frequent cause of DNA reparation impairment. Scientists came to a conclusion that tumor cells with BRCA gene mutation, a number of mechanisms of DNA reparation are switched off. PARP inhibitors, including olaparib, in treatment of BRCA-associated ovarian cancer, potentiates reparation impairments and leads to death of tumor cells..
Vladimir Bulatov, Medical Director of AstraZeneca Russia and Eurasia: “Launch of Lynparza in the Russian market is a major step on the way to AstraZeneca leadership in oncology. This product will lead our portfolio of cancer products, which will not only improve the effectiveness of treatment of patients with cancer, but also significantly contribute to improvement of the quality of life”.
AstraZeneca is an international innovative biopharmaceutical leader involved in research, development and marketing of Rx drugs in cardiology, endocrinology, oncology, respiratory disorders and inflammatory processes, infections and psychiatry. The company is present in over 100 countries, with millions of patients using its innovative drugs.